Belpointe Asset Management LLC Cuts Stake in Hims & Hers Health, Inc. $HIMS

Belpointe Asset Management LLC cut its stake in Hims & Hers Health, Inc. (NYSE:HIMS) by 37.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,745 shares of the company’s stock after selling 2,878 shares during the quarter. Belpointe Asset Management LLC’s holdings in Hims & Hers Health were worth $237,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the business. Northern Trust Corp grew its stake in shares of Hims & Hers Health by 19.5% during the first quarter. Northern Trust Corp now owns 2,435,512 shares of the company’s stock valued at $71,969,000 after acquiring an additional 397,310 shares in the last quarter. Yong Rong HK Asset Management Ltd grew its stake in shares of Hims & Hers Health by 41.2% during the first quarter. Yong Rong HK Asset Management Ltd now owns 2,400,000 shares of the company’s stock valued at $70,920,000 after acquiring an additional 700,100 shares in the last quarter. Nuveen LLC acquired a new stake in shares of Hims & Hers Health during the first quarter valued at about $58,403,000. BIT Capital GmbH grew its stake in shares of Hims & Hers Health by 7.4% during the first quarter. BIT Capital GmbH now owns 1,642,493 shares of the company’s stock valued at $48,536,000 after acquiring an additional 112,949 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its stake in shares of Hims & Hers Health by 1.2% during the first quarter. Bank of New York Mellon Corp now owns 1,260,292 shares of the company’s stock valued at $37,242,000 after acquiring an additional 15,339 shares in the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on HIMS shares. Truist Financial lowered their target price on Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating for the company in a research note on Monday, August 18th. Needham & Company LLC restated a “hold” rating on shares of Hims & Hers Health in a research note on Tuesday, August 5th. Wall Street Zen downgraded Hims & Hers Health from a “buy” rating to a “hold” rating in a research note on Monday, July 28th. UBS Group set a $30.00 price target on Hims & Hers Health in a research note on Monday, June 23rd. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $68.00 price target on shares of Hims & Hers Health in a research note on Friday, September 12th. Two investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Reduce” and a consensus target price of $38.92.

Hims & Hers Health Stock Performance

Shares of HIMS stock opened at $53.98 on Friday. The company has a quick ratio of 4.46, a current ratio of 4.98 and a debt-to-equity ratio of 1.72. The business has a 50 day moving average of $50.86 and a two-hundred day moving average of $48.00. Hims & Hers Health, Inc. has a 52 week low of $17.36 and a 52 week high of $72.98. The company has a market cap of $12.20 billion, a P/E ratio of 67.48, a PEG ratio of 3.64 and a beta of 2.25.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, August 4th. The company reported $0.17 EPS for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The company had revenue of $544.83 million during the quarter, compared to analyst estimates of $550.06 million. During the same quarter in the previous year, the firm earned $0.06 earnings per share. The business’s revenue was up 72.6% on a year-over-year basis. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, insider Patrick Harrison Carroll sold 60,000 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $53.58, for a total value of $3,214,800.00. Following the completion of the transaction, the insider directly owned 169,940 shares in the company, valued at $9,105,385.20. The trade was a 26.09% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Oluyemi Okupe sold 145,000 shares of Hims & Hers Health stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $55.35, for a total value of $8,025,750.00. Following the completion of the transaction, the chief financial officer owned 128,984 shares of the company’s stock, valued at approximately $7,139,264.40. The trade was a 52.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,622,741 shares of company stock worth $83,695,469 over the last ninety days. Company insiders own 13.71% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.